Real-world Leqembi® Study Data at AAIC 2025
Real-world data from 178 early Alzheimer’s disease (AD) patients treated with lecanemab show an 87.4% treatment continuation rate at...
Trethera Gets FDA Clearance for TRE-515 Clinical Trial
The FDA has cleared Trethera Corporation to initiate a clinical trial evaluating TRE-515 in healthy volunteers. This trial will...
Progyny Study Reveals Gap in Women’s Health Benefit Perceptions
A Progyny-Dynata survey of 1,202 women and 252 benefits decision-makers at large US companies reveals a stark disconnect between...
Arbor Biotechnologies Doses First Patient in ABO-101 Gene Editing Study
Arbor Biotechnologies has dosed the first patient in its Phase 1/2 rephine trial of ABO-101, a CRISPR gene editing...
Tenaya Gene Therapies Advance to Clinical Trials Following Positive Safety Reviews
Tenaya Therapeutics announced positive recommendations from independent Data Safety Monitoring Boards (DSMBs) for its two cardiovascular gene therapy trials:...
New Amsterdam Pharma’s Broadway Trial Shows Positive Alzheimer’s Biomarker Reductions
NewAmsterdam Pharma’s cholesteryl ester transfer protein (CETP) inhibitor, obicetrapib, significantly reduced plasma p-tau217 levels, a key Alzheimer’s disease biomarker,...
Vyne Announces Mixed Phase 2b Results for Repibresib Gel in Vitiligo
VYNE Therapeutics’ Phase 2b trial of Repibresib gel for nonsegmental vitiligo failed to meet its primary endpoint of F-VASI50...
Cortec Achieves German BCI Milestone: First Human Brain Implant
CorTec GmbH has implanted its Brain Interchange™ brain-computer interface (BCI) system in a human for the first time. The...
Therini Doses First Patient in Alzheimer’s Trial
Therini Bio has dosed the first patient in a Phase 1b trial of THN391, a monoclonal antibody targeting the...
Vivex Completes Subject Enrollment for Ascend Trial of Via Disc NP
Vivex Biologics has completed enrollment in its ASCEND trial of VIA Disc NP for symptomatic degenerative disc disease (DDD)....